Log In
Print this Print this

REGN2222, SAR438584

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
DescriptionHuman anti-RSV F protein mAb
Molecular Target RSV F protein
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsTreat respiratory syncytial virus (RSV)
Regulatory Designation U.S. - Fast Track (Treat respiratory syncytial virus (RSV))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today